Literature DB >> 26047652

Final pathohistology after radical prostatectomy in patients eligible for active surveillance (AS).

Ekaterina Lellig1, Christian Gratzke, Alexander Kretschmer, Christian Stief.   

Abstract

PURPOSE: The aim of the current study was to determine in retrospect how many of a group of patients who underwent radical prostatectomy were correctly classified with an insignificant prostate carcinoma by means of preoperative diagnostics. Furthermore, we are aiming at finding preoperative parameters which predict an insignificant prostate carcinoma with higher accuracy. The current inclusion parameters of AS will be verified with regard to their reliability, and we will discuss the possibility of improving their prediction accuracy.
METHODS: We examined the data of 308 consecutive patients who were diagnosed with a clinically insignificant prostate carcinoma and therefore would be suited for AS, but opted for a radical prostatectomy. According to the literature(1), the following inclusion criteria were chosen for our evaluation: a proven prostate carcinoma, detected by either ultrasonically guided transrectal core needle biopsy (cT1c) with at least six obtained samples and with a maximum of two positive samples on one side and a less than a 50 % tumor rate per sample, or a 5 % or lower tumor rate found in the tissue obtained by transurethral prostate resection (cT1a). The PSA value in all cases was below 10 ng/ml and the Gleason Score ≤6. The probability of a preoperative "undergrading" or "understaging" was determined as a function of preoperative parameters like Gleason Score, PSA value, the number of collected samples and positive samples obtained by core needle biopsy, prostate volume, and PSA density. Based on the available preoperative data, we developed and tested several regression models for the identification of independent factors for upgrading and upstaging.
RESULTS: Within the examined patient population, 232 of 308 patients (75 %) were, according to their final prostate histology, diagnosed with a stage ≥pT2b prostate carcinoma. Eight percentage of the patients who had undergone surgery had a stage ≥pT3a carcinoma, and 118 of 308 (38 %) had a Gleason Score of 6 or higher. Positive lymph nodes and an infiltration of the seminal vesicle each occurred in 1 % of the cases. Histopathologic positive margins of resection existed in 33 of 308 patients (11 %). Independent factors for upgrading and upstaging a prostate volume of <50 ml and a preoperative Gleason Score of ≤6 were identified.
CONCLUSION: The presented results show that the current inclusion criteria for AS are insufficient. For many patients, the beginning of the necessary therapy is delayed. According to our data, the prostate volume, the preoperative Gleason Score, and the number of positive samples obtained by transrectal core needle biopsy have the highest predictive power with regard to aggressiveness and expansion of the tumor. Despite the consideration of all these preoperative parameters, the differentiation of the prostate carcinomas was underrated in a third of all cases. The expansion of the tumor within the prostate was underrated even in three fourths of the cases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26047652     DOI: 10.1007/s00345-015-1604-6

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  18 in total

1.  A new concept for early recovery after surgery for patients undergoing radical cystectomy for bladder cancer: results of a prospective randomized study.

Authors:  A Karl; A Buchner; A Becker; M Staehler; M Seitz; W Khoder; B Schneevoigt; E Weninger; P Rittler; T Grimm; C Gratzke; C Stief
Journal:  J Urol       Date:  2013-08-19       Impact factor: 7.450

2.  [Active surveillance of low risk prostate cancer].

Authors:  K Lellig; B Beyer; M Graefen; D Zaak; C Stief
Journal:  Urologe A       Date:  2014-07       Impact factor: 0.639

3.  Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance.

Authors:  Ryan K Berglund; Timothy A Masterson; Kinjal C Vora; Scott E Eggener; James A Eastham; Bertrand D Guillonneau
Journal:  J Urol       Date:  2008-09-17       Impact factor: 7.450

4.  Active surveillance can reduce overtreatment in patients with low-risk prostate cancer.

Authors:  Frederik Birkebaek Thomsen; Martin Andreas Røder; Helle Hvarness; Peter Iversen; Klaus Brasso
Journal:  Dan Med J       Date:  2013-02       Impact factor: 1.240

5.  Proceedings: Etiology, epidemiology, and pathology of prostatic cancer.

Authors:  L M Franks
Journal:  Cancer       Date:  1973-11       Impact factor: 6.860

Review 6.  Active surveillance for clinically localized prostate cancer--a systematic review.

Authors:  Frederik B Thomsen; Klaus Brasso; Laurence H Klotz; M Andreas Røder; Kasper D Berg; Peter Iversen
Journal:  J Surg Oncol       Date:  2014-03-07       Impact factor: 3.454

7.  Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.

Authors:  Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

Review 8.  Insignificant prostate cancer and active surveillance: from definition to clinical implications.

Authors:  Patrick J Bastian; Ballentine H Carter; Anders Bjartell; Michael Seitz; Peter Stanislaus; Francesco Montorsi; Christian G Stief; Fritz Schröder
Journal:  Eur Urol       Date:  2009-03-06       Impact factor: 20.096

9.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.

Authors:  Laurence Klotz; Liying Zhang; Adam Lam; Robert Nam; Alexandre Mamedov; Andrew Loblaw
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

10.  Pathological features after radical prostatectomy in potential candidates for active monitoring.

Authors:  Christopher R Griffin; Xiaoying Yu; Stacy Loeb; Vic N Desireddi; Misop Han; Theresa Graif; William J Catalona
Journal:  J Urol       Date:  2007-07-16       Impact factor: 7.450

View more
  7 in total

1.  Management of low- and intermediate-risk prostate cancer.

Authors:  Henk van der Poel; Laurence Klotz; Christian G Stief
Journal:  World J Urol       Date:  2015-07       Impact factor: 4.226

Review 2.  [Radical prostatectomy as part of a multimodal concept for patients with prostate cancer and bone metastases at initial diagnosis].

Authors:  A Spek; A Herlemann; C Gratzke; C G Stief
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

3.  Postoperative upgrading of prostate cancer in men ≥75 years: a propensity score-matched analysis.

Authors:  Annika Herlemann; Alexander Buchner; Alexander Kretschmer; Maria Apfelbeck; Christian G Stief; Christian Gratzke; Stefan Tritschler
Journal:  World J Urol       Date:  2017-05-10       Impact factor: 4.226

Review 4.  [Localized intermediate- to high-risk prostate cancer].

Authors:  S Tritschler; U Ganswindt; C G Stief
Journal:  Urologe A       Date:  2016-03       Impact factor: 0.639

5.  Pathologic correlation of transperineal in-bore 3-Tesla magnetic resonance imaging-guided prostate biopsy samples with radical prostatectomy specimen.

Authors:  Erik Velez; Andriy Fedorov; Kemal Tuncali; Olutayo Olubiyi; Christopher B Allard; Adam S Kibel; Clare M Tempany
Journal:  Abdom Radiol (NY)       Date:  2017-08

6.  [Active surveillance for low-risk prostate cancer].

Authors:  Annika Herlemann; Christian G Stief
Journal:  Urologe A       Date:  2016-02       Impact factor: 0.639

7.  Current concepts in multiparametric magnetic resonance imaging for active surveillance of prostate cancer.

Authors:  Alexandre Cavalcante; Públio Cesar C Viana; Giuliano B Guglielmetti; José Pontes Junior; Henrique Nonemacher; Mauricio D Cordeiro; Regis Otaviano F Bezerra; Rafael F Coelho; William Carlos Nahas
Journal:  Clinics (Sao Paulo)       Date:  2018-12-10       Impact factor: 2.365

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.